EXOZYMES (EXOZ) VP awarded 3,999 common shares as stock grant

Rhea-AI Filing Summary

Opgenorth Paul Hideo reported acquisition or exercise transactions in this Form 4 filing.

EXOZYMES INC. reported that Vice President of Development Paul Hideo Opgenorth received a grant of 3,999 shares of common stock on April 1, 2026 at a price of $8.44 per share. Following this compensation-related award, his direct holdings increased to 645,149 shares of EXOZYMES common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Opgenorth Paul Hideo

Role Vice President, Development

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	3,999	$8.44	$34K

Holdings After Transaction: COMMON STOCK — 645,149 shares (Direct)

Footnotes (1)

Key Figures

Shares granted: 3,999 shares Grant price: $8.44 per share Post-transaction holdings: 645,149 shares

3 metrics

Shares granted 3,999 shares Common stock grant on April 1, 2026

Grant price $8.44 per share Reported transaction price for the stock award

Post-transaction holdings 645,149 shares Direct ownership after the April 1, 2026 grant

Key Terms

COMMON STOCK, Grant, award, or other acquisition, Form 4

3 terms

COMMON STOCK financial

"security_title: "COMMON STOCK""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Opgenorth Paul Hideo

(Last) (First) (Middle)

C/O 750 ROYAL OAKS DRIVE, SUITE 106

(Street)

MONROVIA CALIFORNIA 91016

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXOZYMES INC. [ EXOZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President, Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	04/01/2026	04/01/2026	A		3,999	A	$8.44	645,149	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Paul Opgenorth	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did EXOZ (EXOZYMES INC.) disclose in this Form 4?

EXOZYMES INC. disclosed that Vice President of Development Paul Hideo Opgenorth received a grant of 3,999 shares of common stock. The award was reported at a price of $8.44 per share and reflects compensation rather than an open-market purchase.

Who is the insider involved in the latest EXOZ Form 4 filing?

The insider is Paul Hideo Opgenorth, Vice President of Development at EXOZYMES INC. He reported receiving 3,999 shares of common stock as a grant, classified as a “grant, award, or other acquisition” under transaction code A.

How many EXOZ shares did the insider receive and at what price?

Paul Hideo Opgenorth received 3,999 shares of EXOZYMES common stock. The Form 4 lists a transaction price of $8.44 per share, characterizing the event as a grant or award rather than a market trade.

What are Paul Hideo Opgenorth’s EXOZ holdings after this transaction?

After the reported grant, Paul Hideo Opgenorth directly holds 645,149 shares of EXOZYMES INC. common stock. This figure, disclosed in the Form 4, shows his total direct ownership following the April 1, 2026 award.

Was the EXOZ insider transaction a market buy or a compensation grant?

The transaction was a compensation-related grant, not an open-market buy. It is coded “A” on the Form 4 and described as a grant, award, or other acquisition of 3,999 shares of EXOZYMES common stock.

Does the EXOZ Form 4 show any stock sales by the insider?

No stock sales are shown in this Form 4. The filing reports only one acquisition transaction, a grant of 3,999 shares of EXOZYMES common stock to Vice President of Development Paul Hideo Opgenorth, with no disposals reported.